XLO Insider Trading Activity and SEC Form 4 Filings
XLO insider trading summary
Over the past 12 months, insiders at Xilio Therapeutics, Inc. (XLO) reported 2 sales worth $6K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $6K.
Latest XLO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 2, 2026 | Christopher James Frankenfield | Chief Financial Officer | Sell | $5K (7,030 @ $0.64) |
| Jan 2, 2026 | Kevin M. Brennan | SVP, Finance and Accounting | Sell | $1K (1,826 @ $0.64) |
| Jun 17, 2025 | James Samuel Shannon | Insider | Buy | $17K (25,000 @ $0.69) |
| Jun 16, 2025 | James Samuel Shannon | Insider | Buy | $31K (45,000 @ $0.69) |
| Jun 16, 2025 | Rene Russo | President and CEO | Buy | $25K (36,289 @ $0.68) |
| Jan 2, 2025 | Kevin M. Brennan | SVP, Finance and Accounting | Sell | $2K (1,803 @ $0.98) |
| Jan 2, 2025 | Christopher James Frankenfield | Chief Financial Officer | Sell | $7K (6,954 @ $0.98) |
| Dec 18, 2024 | Gilead Sciences, Inc. | 10% Owner | Buy | $1.8M (1,759,978 @ $1.04) |
| Apr 2, 2024 | Gilead Sciences, Inc. | 10% Owner | Buy | $369K (485,250 @ $0.76) |
| Feb 8, 2024 | Atlas Venture Associates Opportunity I, L.P. | 10% Owner | Sell | $469 (733 @ $0.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.